282 related articles for article (PubMed ID: 25686120)
1. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
3. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
4. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
Wadleigh M; DeAngelo DJ; Griffin JD; Stone RM
Blood; 2005 Jan; 105(1):22-30. PubMed ID: 15358622
[TBL] [Abstract][Full Text] [Related]
5. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
6. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
7. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
8. Reversible phosphorylation in haematological malignancies: potential role for protein tyrosine phosphatases in treatment?
Ruela-de-Sousa RR; Queiroz KC; Peppelenbosch MP; Fuhler GM
Biochim Biophys Acta; 2010 Dec; 1806(2):287-303. PubMed ID: 20659529
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
[No Abstract] [Full Text] [Related]
10. [Molecularly target therapy].
Kiyoi H
Nihon Rinsho; 2012 Apr; 70 Suppl 2():211-6. PubMed ID: 23133955
[No Abstract] [Full Text] [Related]
11. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
12. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon Y; Schwaller J
Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
[TBL] [Abstract][Full Text] [Related]
13. [Protein tyrosine kinase inhibitors in cancer therapy].
Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
[TBL] [Abstract][Full Text] [Related]
14. [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Lipka D; Heidel F; Huber C; Fischer T
Pharm Unserer Zeit; 2008; 37(5):394-403. PubMed ID: 18729264
[No Abstract] [Full Text] [Related]
15. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
16. MUC1 in hematological malignancies.
Stroopinsky D; Kufe D; Avigan D
Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
[TBL] [Abstract][Full Text] [Related]
17. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
18. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
20. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Jabbour E; Ottmann OG; Deininger M; Hochhaus A
Haematologica; 2014 Jan; 99(1):7-18. PubMed ID: 24425689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]